Purpose
To develop a genomic signature that predicts benefit from trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.Patients and methods
DASL technology was used to quantify mRNA in samples from 1,282 patients enrolled onto the Combination Chemotherapy Wi...